drugset
drugset / Trial / NCT06106022

A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease

NCT06106022 ↗

Phase 1 Completed 22 enrolled Phathom Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily \[QD\]) in children ≥ 6 to \< 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).

Timeline

Start
2023-11-01
Primary completion
2024-04-16
Completion
2024-04-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 10 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral

Indications

gastroesophageal reflux disease